bay1834845
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 13, 2017 (NCT03054402)
Timeline
Indications
Mechanism of action
IRAK4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bay1834845
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05656911 | Phase 2 | Dec 21, 2022 | Bayer |
| NCT05003089 | Phase 1 | Jun 28, 2021 | Bayer |
| NCT03493269 | Phase 1 | Apr 16, 2018 | Bayer |
| NCT03244462 | Phase 1 | Aug 18, 2017 | Bayer |
| NCT03054402 | Phase 1 | Feb 13, 2017 | Bayer |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 5 | 5 | 2 | 2017 |
1 organizations
Page 1 / 1